Acute Respiratory Distress Syndrome Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AVM Biotechnology, Aqualung Therapeutics, Cynata Therapeutics, His

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Respiratory Distress Syndrome pipeline constitutes 50+ key companies continuously working towards developing 50+ Acute Respiratory Distress Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Acute Respiratory Distress Syndrome Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.

The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years.
• Acute Respiratory Distress Syndrome companies working in the treatment market are Meridigen Biotech, AVM Biotechnology, Aqualung Therapeutics, Cynata Therapeutics, Histocell, BioMarck Pharmaceuticals, Exvastat, Vasomune Therapeutics, Athersys, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment
• Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- UMC 119 06, AVM0703, ALT-100, CYP 001, HCR040, BIO-11006, Imatinib, AV 001, MultiStem cell therapy, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.
• In February 2021, In a statement, Athersys stated that it had collaborated with HEALIOS. The goal of the cooperation agreement is to reaffirm the parties' shared dedication to the cooperative growth of MultiStem in Japan.
• In March 2021, SIRS Therapeutics and F4 Pharma signed a licensing and collaboration agreement with Partner Therapeutics to help with the development of FX-06. There are numerous potential uses for this synthetic peptide.
• In June 2020, The US FDA granted NeuroRx Fast Track designation for the exploration of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome linked to COVID-19, according to an announcement made by NeuroRx in collaboration with Relief Therapeutics.

Acute Respiratory Distress Syndrome Overview
Low blood oxygen levels are a result of the dangerous lung ailment acute respiratory distress syndrome (ARDS). People who have ARDS typically become unwell as a result of another illness or a serious injury. In ARDS, surfactant disintegrates and fluid accumulates inside the lungs' small air sacs. A frothy material called asurfactant maintains the lungs open so that one can breathe.

Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:
• UMC 119 06: Meridigen Biotech
• AVM0703: AVM Biotechnology
• ALT-100: Aqualung Therapeutics
• CYP 001: Cynata Therapeutics
• HCR040: Histocell
• BIO-11006: BioMarck Pharmaceuticals
• Imatinib: Exvastat
• AV 001: Vasomune Therapeutics
• MultiStem cell therapy: Athersys
• HLCM051(MultiStem): Healios

Acute Respiratory Distress Syndrome Route of Administration
Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Subcutaneous
• Intramuscular
• Intravenous
• Molecule Type

Acute Respiratory Distress Syndrome Molecule Type
Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as
• Monoclonal antibodies
• Stem cell therapies
• Immunoproteins
• Peptides
• Proteins
• Product Type

Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment
• Acute Respiratory Distress Syndrome Assessment by Product Type
• Acute Respiratory Distress Syndrome By Stage and Product Type
• Acute Respiratory Distress Syndrome Assessment by Route of Administration
• Acute Respiratory Distress Syndrome By Stage and Route of Administration
• Acute Respiratory Distress Syndrome Assessment by Molecule Type
• Acute Respiratory Distress Syndrome by Stage and Molecule Type

DelveInsight's Acute Respiratory Distress Syndrome Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies at:
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:
Key companies developing therapies for Acute Respiratory Distress Syndrome are - Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others.

Acute Respiratory Distress Syndrome Pipeline Analysis:
The Acute Respiratory Distress Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.
• Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies-
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Respiratory Distress Syndrome Pipeline Market Drivers
• Increasing R&D activities, increasing incidence of ARDS, non-competitive Landscape are some of the important factors that are fueling the Acute Respiratory Distress Syndrome Market.

Acute Respiratory Distress Syndrome Pipeline Market Barriers
• However, lack of awareness about the disease, mechanical ventilation for management, missed-diagnoses of ARDS and other factors are creating obstacles in the Acute Respiratory Distress Syndrome Market growth.

Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Acute Respiratory Distress Syndrome Companies: , and others
• Key Acute Respiratory Distress Syndrome Therapies: UMC 119 06, AVM0703, ALT-100, CYP 001, HCR040, BIO-11006, Imatinib, AV 001, MultiStem cell therapy, and others
• Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
• Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers

Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Acute Respiratory Distress Syndrome Report Introduction
2. Acute Respiratory Distress Syndrome Executive Summary
3. Acute Respiratory Distress Syndrome Overview
4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Acute Respiratory Distress Syndrome Pipeline Therapeutics
6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)
7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)
8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I)
9. Acute Respiratory Distress Syndrome Preclinical Stage Products
10. Acute Respiratory Distress Syndrome Therapeutics Assessment
11. Acute Respiratory Distress Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Acute Respiratory Distress Syndrome Key Companies
14. Acute Respiratory Distress Syndrome Key Products
15. Acute Respiratory Distress Syndrome Unmet Needs
16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers
17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion
18. Acute Respiratory Distress Syndrome Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Acute Respiratory Distress Syndrome Market https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Respiratory Distress Syndrome-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Acute Respiratory Distress Syndrome Epidemiology https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Respiratory Distress Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Multiple Myeloma Market https://www.delveinsight.com/report-store/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Multiple Myeloma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of multiple myeloma, historical and forecasted epidemiology as well as multiple myeloma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.